November 20, 2025

Here's how the PD-(L)1xVEGF bispecific race is looking so far

IntelME Verdict

Clinical Breakthrough

TL;DR

Key PD-(L)1xVEGF bispecific antibodies, like Pumitamig and Ivonescimab, show promising results in clinical trials for lung cancers, offering potential dual pathway benefits.

Analysis

The emergence of promising PD-(L)1xVEGF bispecific antibodies like Pumitamig and Ivonescimab signifies a clinical breakthrough in lung cancer treatment. These dual pathway agents offer potential for improved outcomes in challenging cancers, showcasing the evolving landscape of targeted therapies and the potential for enhanced patient care.

Source

Endpoints News↗